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Mutations in superoxide dismutase 1 (SOD1) are associated with familial cases of amyotrophic lateral scler-
osis (fALS). Studies in transgenic mice have suggested that wild-type (WT) SOD1 can modulate the toxicity of
mutant SOD1. In the present study, we demonstrate that the effects of WT SOD1 on the age at which trans-
genic mice expressing mutant human SOD1 (hSOD1) develop paralysis are inﬂuenced by the nature of the
ALS mutation and the expression levels of WT hSOD1. We show that regardless of whether WT SOD1
changes the course of disease, both WT and mutant hSOD1 accumulate as detergent-insoluble aggregates
in symptomatic mice expressing both proteins. However, using a panel of ﬂuorescently tagged variants of
SOD1 in a cell model of mutant SOD1 aggregation, we demonstrate that the interactions between mutant
and WT SOD1 in aggregate formation are not simply a co-assembly of mutant and WT proteins. Overall,
these data demonstrate that the product of the normal SOD1 allele in fALS has potential to inﬂuence the tox-
icity of mutant SOD1 and that complex interactions with the mutant protein may inﬂuence the formation of
aggregates and inclusion bodies generated by mutant SOD1.
INTRODUCTION
Familial amyotrophic lateral sclerosis (fALS) is a severe
motor neuron disease caused, in  20% of cases, by mutations
in superoxide dismutase 1 (SOD1) (1). To date, over 150
mutations in the coding sequence of SOD1 have been ident-
iﬁed in ALS patients; most mutations are point substitutions
but a few produce truncated proteins due to early termination
(for most recent list, see http://alsod.iop.kcl.uk, last date
accessed 09/30/2010). ALS-associated mutations in SOD1,
both missense and premature termination, induce misfolding
and aggregation of the protein (2,3). In studies of G93A trans-
genic mice that model SOD1-fALS, sedimentable
detergent-insoluble aggregates of mutant SOD1 ﬁrst begin to
accumulate at approximately the time that symptoms
become ﬁrst noticeable (at  80 days of age) (4,5). Similar
data have been observed in multiple lines of ALS mice, with
the levels of insoluble SOD1 in the spinal cord dramatically
accumulating over the last few weeks of life (6). Both theor-
etical models (7) and cell culture models (3) have produced
data to suggest that mutations imparting a high propensity to
aggregate are disproportionately associated with disease of
shorter duration. Thus, we have proposed that large aggregates
may modulate the rate of disease progression in humans with
forms of mutant SOD1 that are soluble being responsible for
initiating disease (3,6).
The molecular features of the mutant SOD1 responsible
for initiating disease have yet to be deﬁned. Recent studies
have focused our attention on the possible role of WT
SOD1 as a modulator of disease initiation. In transgenic
mice, co-expression of high levels of WT human SOD1
(hSOD1) with mutant hSOD1 (A4V, G85R, G93A, T116X
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age to onset and paralysis with no obvious change in the rate
of progression from onset to paralysis (8–11). In mice that
express mutants in which the mutant protein is easily distin-
guished from WT SOD1, such as the G85R, T116X and
L126Z mutants, it has been possible to determine that
earlier disease onset is accompanied by the formation of
detergent-insoluble aggregates that appear to contain both
WT hSOD1 and mutant hSOD1 (8,9,11). However, in cul-
tured cell models, WT hSOD1 does not promote the aggrega-
tion of mutant SOD1, but rather seems to slow the process
(12,13). In vitro, small amounts of immature mutant SOD1
can seed the aggregation of WT SOD1 (14). Collectively,
these studies indicate a potential for WT hSOD1 to play a
role in the aggregation of mutant SOD1 and to modulate
the course of disease.
Although the foregoing evidence is compelling, initial
studies to investigate the role of WT hSOD1 as a modulator
of disease produced conﬂicting outcomes. Bruijn et al.( 15)
reported that co-expressing WT and G85R hSOD1 had no
effect on disease onset or survival. In the present study,
we have directly compared the WT hSOD1 mouse line
used in the Bruijn study [designated line 76 (16)] with
the line used in the studies by Deng et al. (described in
17) to determine the degree to which the source of WT
hSOD1 expression affects the age at which co-expressed
mutant SOD1 causes paralysis. We have also used cell
models to examine interactions between WT and mutant
hSOD1 in aggregate formation. Our ﬁndings demonstrate
that the effect of WT hSOD1 on age to paralysis in
mutant SOD1 transgenic mice is inﬂuenced by the nature
of the mutation and the expression level of WT SOD1.
We also demonstrate that the assembly of large aggregates
that include WT protein, in mice co-expressing WT and
mutant SOD1, is secondary to the processes that are respon-
sible for accelerating the age to paralysis.
RESULTS
Studies involving matings of mice that over-express WT
hSOD1 to mice that over-express mutant hSOD1 have
reported differing outcomes depending on the strain of WT
hSOD1 mice used. A study by Bruijn et al.( 15) reported
that WT hSOD1 expressed from a line of mice developed by
Wong et al. [line 76; (16)] had no effect on the course of
disease caused by G85R hSOD1. In contrast, multiple
studies have reported that WT hSOD1 expressed from a line
of mice developed by Gurney et al.( 17) accelerates the
course of disease caused by mutant hSOD1 (8–10), including
the G85R variant of hSOD1 (11). To determine whether the
different lines of WT hSOD1 mice used in these studies
account for the different outcomes, we crossed three different
strains of WT hSOD1 mice to mice expressing either G37R or
L126Z hSOD1 proteins. The three WT hSOD1 strains of mice
used were: (i) B6SJL-Tg(SOD1)2Gur/J hybrid line (SJLWT)
(17), (ii) B6/L76WT SOD1 Wong congenic line (L76WT)
(16) and (iii) a variant of the B6SJL-Tg(SOD1)2Gur/J
Gurney hybrid line (17), here termed congenic (Cg) WT,
that was backcrossed to C57BL/6J to create a strain possessing
an equivalent background to that of the B6/L76WT SOD1
congenic line.
Expression of WT SOD1 in the Gurney and L76 lines
of transgenic mice
We compared side by side the levels of hSOD1 mRNA and
protein in the different WT hSOD1 mouse strains used in
this study, using northern and immunoblot analyses (Fig. 1).
In young mice ( 3–4 months of age), the levels of hSOD1
mRNA in spinal cords from the Gurney strains of WT
SOD1 mice, both the SJLWT and the CgWT lines, were
found to be  30% higher than those of L76WT hSOD1
mice (Fig. 1A and B). Correspondingly, the levels of hSOD1
protein in spinal cords of the Gurney strains were also 30%
higher than those of L76WT mice (Fig. 1C and D). In all
strains of mice, most of the WT SOD1 in the spinal cord
appeared to be properly post-translationally modiﬁed by an
intramolecular disulﬁde bond (Supplementary Material,
Fig. S1).
In studies of L76WT mice and various lines of mutant
SOD1 mice, we have viewed WT hSOD1 as being relatively
resistant to aggregation (2,6,18,19). Jonsson et al.( 5) reported
that spinal cords of older Gurney SJLWT mice accumulate
detergent-insoluble forms of WT hSOD1. However, the con-
centrations of detergent used in Jonsson’s study were lower
than our protocol, and insoluble forms of WT hSOD1 were
detected in young and older mice (5). Our methodology,
which uses higher concentrations of non-ionic detergent and
possibly higher detergent to protein ratios (6), routinely solu-
bilizes nearly all mutant hSOD1 in spinal cords of asympto-
matic mice expressing mutant hSOD1 (6) and all WT
hSOD1 in spinal cords of adult L76WT mice (2,6). Applying
our methodology, we detected small amounts of detergent-
insoluble WT hSOD1 in spinal cords of older Gurney WT
SOD1 mice but not in L76WT mice (Fig. 2). Speciﬁcally, in
the Gurney line of WT mice, in both SJL and Cg WT
strains, signiﬁcant accumulations of aggregated WT SOD1
protein were found as early as 8 months (SJLWT), and
increased to higher levels at 11 (SJLWT) and 17 (CgWT)
months of age (Fig. 2A and B). However, in L76WT SOD1
mice, the accumulation of detergent-insoluble protein was
negligible at 17 months of age (Fig. 2A and B). In an analysis
of total protein levels in all three strains of mice, we noted that
the total levels of WT SOD1 were higher in spinal cords of the
older mice (Supplementary Material, Fig. S2). Thus, even
though we did not detect detergent-insoluble aggregates in
spinal cords of the L76 mice, there was evidence of an
accumulation of the protein. Importantly, the relative aggrega-
tion index of WT hSOD1 protein in all of the WT SOD1 lines
of mice was not as high as mutant G37R hSOD1 in sympto-
matic G37R Line 29 hSOD1 mice [genomic hSOD1 construct
(16)] (Gn.G37R, Fig. 2A and B), which develop disease at
 7 months of age and which accumulate relatively low
levels of aggregated hSOD1 at disease endstage (6). Thus,
the Gurney strains of mice exhibit a spontaneous aggregation
of WT hSOD1, but the levels appear to be below the threshold
to induce ALS phenotypes or such assemblies of the WT
protein do induce the full spectrum of disease phenotypes.
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mice expressing the G37R fALS variant develop paralysis
The three different strains of WT mice were bred to two differ-
ent lines of mutant SOD1 mice. One mutant line expresses the
G37R variant of hSOD1 from a vector that utilizes the mouse
prion promoter (PrP.SOD1-G37R line 110, designated
hereafter simply as G37R), which drives transgene expression
primarily in muscle and neural tissue (20). The expression
levels of the transgene in heterozygous G37R mice are
known to be too low to produce an ALS phenotype in mice
(20). However, when G37R expression levels are increased
by breeding the mice to homozygosity, the resulting mice
manifest typical ALS symptoms and pathology (20). Thus,
whereas heterozygous G37R mice do not develop ALS over
the course of their 2 year lifespan, homozygous G37R mice
develop paralysis at  8 months of age (Fig. 3A). The other
mutant SOD1 mouse line that we used expresses the L126Z
SOD1 transgene, which is controlled by the normal hSOD1
gene promoter and consists of modiﬁed genomic SOD1 (19).
The age at which these mice develop paralysis is also
8 months (Fig. 3B). We obtained a total of ﬁve different types
of double-transgenic mice expressing WT and mutant hSOD1
proteins: G37R/SJLWT, G37R/CgWT, G37R/L76WT,
L126Z/SJLWT and L126Z/L76WT. In the case of crosses of
G37R mice to the three strains of WT hSOD1 mice,
co-expression of both the WT and G37R protein induced
paralysis earlier than what occurs in homozygous G37R mice
(paralyzed at 8 months: 252.6+4.75 days, N ¼ 20). In
G37R/SJLWT mice, we observed paralysis by 5 months of
age (160.1+2.40 days, N ¼ 18); the G37R/CgWT SOD1
became paralyzed at  6 months of age (190.1+1.01 days,
N ¼ 7); whereas in G37R/L76WT mice, we observed paralysis
at  7 months of age (213.8+4.35 days, N ¼ 13) (Fig. 3A). In
this experiment, littermate mice that were heterozygous for the
G37R SOD1 transgene were aged only to 12 months (N . 25),
remaining free of disease. In prior experiments, heterozygous
G37R mice have been shown to reach ages of .20 months
without developing disease (20).
Similar to the outcome described above, in double-
transgenic mice harboring WT and L126Z hSOD1 proteins,
we observed earlier onsets of paralysis in L126Z/WT mice
in which the WT hSOD1 transgene was derived from the
Gurney WT strain of mice. L126Z/SJLWT mice developed
Figure 1. Expression of WT hSOD1 in Gurney and L76 lines of mice. (A) Northern blot of hSOD1 mRNA in spinal cords of WT mice used in this study. A probe
for mRNA of the endogenous mouse prion protein (PrP) gene was used as a loading control. (B) Quantiﬁcation of the mRNA levels normalized to the PrP
control. (C) Immunoblot analysis of the same spinal cords with a hSOD1 antibody. Antibody recognizing b-tubulin III was used as a loading protein
control. (D) Quantiﬁcation of the human WT protein levels normalized to loading control. Signiﬁcant differences were found in RNA and protein levels
between L76WT and each of the Gurney strains of mice (P ≤ 0.05) but not between the SJL and Cg WT Gurney strains. (B) and (D) were assessed by unpaired
Student’s t-tests: ∗P ≤ 0.05,
#P ≤ 0.005. Bars represent mean+SEM of three different spinal cords for each mouse line.
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N ¼ 10; Fig. 3B), which was  1–2 months earlier than het-
erozygous mice expressing only L126Z SOD1 (214.1+
3.74 days,
N ¼ 53). However, L126Z/L76WT double-transgenic mice
did not develop paralysis until 8 months of age (224.8+
6.41 days, N ¼ 16; Fig. 3B), which was the same age at
which heterozygous mice transgenic for only L126Z SOD1
developed paralysis. Thus, in this experiment, it would
appear that a higher level of WT hSOD1 expression was
required to alter age to paralysis in the L126Z mice.
Accumulation of WT SOD1 in detergent-insoluble
aggregates in symptomatic mice co-expressing
mutant SOD1
Previous studies have established that spinal cords of paral-
yzed mice co-expressing WT and mutant hSOD1 accumulate
detergent-insoluble forms of both mutant and WT proteins
(8). Similar to this previous report, we detected detergent-
insoluble forms of SOD1 in spinal cords of endstage G37R/
WT mice (Fig. 4A, P2). The levels of SOD1 in the
detergent-insoluble (P2) and soluble (S1) fractions were quan-
tiﬁed and graphed as the ratio of SOD1 in P2 versus S1; we
refer to this value as aggregation index (see Materials and
Methods). In all symptomatic G37R/WT mice, the accumu-
lation of detergent-insoluble SOD1 species was signiﬁcantly
higher than asymptomatic heterozygous G37R mice, which
accumulate little or no detergent-insoluble aggregates
(Fig. 4B). The aggregation index for total SOD1 in spinal
cords of symptomatic G37R/WT mice was similar to that of
symptomatic homozygous G37R mice (Fig. 4B). We also
determined that most of the SOD1 protein in spinal cords of
the G37R/WT mice possessed the normal intramolecular dis-
ulﬁde bond, indicating that the excess burden of WT SOD1
did not greatly alter the ability of the system to properly
process both WT and mutant SOD1 (Supplementary Material,
Fig. S3). Thus, symptomatic mice co-expressing G37R and
WT SOD1 accumulated detergent-insoluble forms of SOD1.
Similarly, symptomatic mice co-expressing L126Z and
WT SOD1 accumulated detergent-insoluble forms of SOD1.
In these animals, the WT and L126Z proteins can be distin-
guished on immunoblots due to the smaller size of the trun-
cated mutant protein. In all symptomatic L126Z/WT mice,
we detected detergent-insoluble forms of WT and mutant
SOD1 proteins (Fig. 4C). Note, as described previously (19),
we were unable to detect detergent-soluble forms of the
L126Z protein (Fig. 4C; Supplementary Material, Fig. S1).
In spinal cords of both the L126Z/SJLWT and L126Z/
L76WT, the amount of insoluble WT hSOD1 was approxi-
mately equivalent to insoluble L126Z protein (Fig. 4D). In
comparison with symptomatic heterozygous mice that
express the L126Z alone, spinal cords of symptomatic mice
co-expressing WT and L126Z SOD1 accumulated higher
total levels of insoluble SOD1 (Fig. 4D, add values for
L126Z and WT in the insoluble fractions). In L126Z/
L76WT mice, the levels of insoluble L126Z protein were sig-
niﬁcantly higher than the levels of that in heterozygous mice
expressing L126Z alone. This ﬁnding indicates that the
higher levels of total SOD1 in spinal cords of these animals
stimulate the generation of these aggregates. However, and
importantly, insoluble WT hSOD1 was detected in spinal
cords of symptomatic L126Z/L76WT mice (Fig. 4C) even
though these mice show an age to paralysis that is identical
to that of mice expressing the L126Z mutant alone. This
ﬁnding indicates that induced aggregation of WT hSOD1 is
not sufﬁcient to decrease the age to paralysis.
In our immunoblot analyses of detergent-insoluble SOD1 in
the G37R/WT mice, it was not possible to determine whether
WT acquired insolubility by standard immunoblot of SDS–
PAGE. In order to determine whether detergent-insoluble
forms of WT hSOD1 accumulate in G37R mice, we analyzed
the detergent-insoluble fractions of spinal cords from sympto-
matic G37R/SJLWT mice by hybrid linear ion-trap Fourier-
transformation ion cyclotron resonance mass spectrometry
(FTMS) analyses. In two different pooled samples of spinal
cords from G37R/SJLWT mice we detected both WT and
G37R SOD1 in the detergent-insoluble fraction (Fig. 5A and
B). As expected, WT and G37R SOD1 proteins were detected
in the soluble S1 fractions (Fig. 5C and D). However, in the
soluble fraction, the level of the mutant protein detected by
mass spectroscopy was much lower than expected. Based on
Figure 2. Low levels of WT hSOD1 aggregates in spinal cords of older Gurney mice. Spinal cords from Gurney strains (SJL and Cg) of mice, but not from L76
mice, contain detergent-insoluble aggregates of WT SOD1. (A) Immunoblots of S1 and P2 fractions of mice expressing WT hSOD1 at varied ages. An antibody
that recognizes mouse and hSOD1 was used. NTg, non-transgenic mice. Gn.G37R denotes symptomatic aged mice ( 7 months) that harbor human genomic
fragments of the SOD1 gene (line 29)—mice that were originally described by Wong et al.( 16). (B) Quantiﬁcation of the aggregation index. Unpaired Student’s
t-tests were performed to establish signiﬁcant differences as indicated: ∗P ≤ 0.05,
#P ≤ 0.005. Bars represent mean+SEM.
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(Supplementary Material, Fig. S4), we would have expected
the signal intensity for G37R to be 50% of that of the signal
for WT SOD1. However, the signal for G37R SOD1 in the
soluble fractions was ,10% of the WT protein signal.
Because the detection of the G37R mutant in soluble fractions
was less than expected, we suspect that the detection of the
G37R protein by mass spectroscopy is less efﬁcient than the
detection of WT protein. Therefore, the relative amount of
the G37R protein in the insoluble fraction could be much
greater than indicated by the mass spectroscopic analysis of
the insoluble fractions. From these data, we can conclude
that WT SOD1 is present in the insoluble fractions from
spinal cords but we cannot be sure of the relative amount of
each protein.
Formation of detergent-insoluble aggregates of WT
and mutant SOD1 in cell culture models
The foregoing ﬁndings, along with prior work by Deng et al.
(8), demonstrate that high-level expression of WT SOD1 in
some manner heightens the toxicity of mutant SOD1 to
decrease the age at which paralysis develops. In cell culture
models of aggregation, we have noted that co-expression of
WT and mutant SOD1 at 1:1 ratios inhibits the aggregation
of mutant SOD1 (12). Here, we evaluated the ability of WT
hSOD1 to modulate the aggregation of G37R and L126Z
hSOD1 mutant proteins in cell culture. Co-expression of WT
and G37R hSOD1 proteins (24 h incubations) did not
produce detectable levels of aggregated hSOD1 proteins
(Fig. 6A and B, 24 h). At 48 h after transfection, similar to
what we have observed previously with other ALS mutants
(A4V, G85R, G93A) (12), we observed signiﬁcant accumu-
lation of aggregated SOD1 proteins in cells co-transfected
with WT + G37R hSOD1 expression plasmids (Fig. 6A).
However, the total amount of aggregated SOD1 in the insolu-
ble fraction was lower in the cells expressing WT and G37R
compared with cells co-expressing G37R SOD1 and green ﬂu-
orescent protein (GFP; GFP serves as a control for non-
speciﬁc effects of co-transfection) (Fig. 6A and B, 48 h). In
co-transfections of WT hSOD1 with the L126Z hSOD1 trunca-
tion mutant, we evaluated aggregation index only at the 48 h
transfection interval because the L126Z mutant was inherently
slower to produce aggregates in the cell model. Cells
expressing only L126Z hSOD1 accumulated aggregated
protein and small quantities of soluble protein (Fig. 6C and
D). However, in cells co-transfected with L126Z + WT
hSOD1, detergent-insoluble forms of either protein were vir-
tually undetectable (Fig. 6C and D). A difﬁcult aspect of
this experiment is that in contrast to WT protein, the L126Z
protein was not readily detected in the soluble fraction of
the co-transfected cell lysates as one might expect if aggrega-
tion was inhibited (Fig. 6C). This result was repeatedly
observed in multiple transfections (Supplementary Material,
Fig. S5). The L126Z mutant is relatively rapidly degraded
and fails to accumulate to appreciable levels except as insolu-
ble aggregates. It appears that when the aggregation of the
L126Z protein is inhibited by WT SOD1, then the mutant is
rapidly degraded. In the co-transfection control (L126Z
hSOD1 + GFP), the aggregation of the L126Z protein
was reduced due to a reduced expression of total mutant
protein, but the levels of aggregated L126Z protein remained
signiﬁcantly higher than those of cells co-expressing L126Z
and WT hSOD1 (Fig. 6C and D). These ﬁndings indicate
that, in our cell model, the presence of WT SOD1 produces
a pronounced slowing of the formation of the large sedimen-
table aggregates for both the G37R and L126Z mutants.
Complex interactions between WT and mutant SOD1
in aggregate assembly
To visualize interactions between WT and mutant hSOD1 in
the formation of inclusions, we created a series of hSOD1 pro-
teins fused to the YFP or RFP variants of GFP. Normally, YFP
and RFP are diffusely distributed throughout the cell cyto-
plasm (Fig. 7A–F). A fusion of WT hSOD1 with YFP
(WT::YFP) produced a protein that was diffusely distributed
throughout the cell similar to YFP alone (Fig. 7G–I). In con-
trast, WT hSOD1 fused to RFP (WT::RFP) rapidly formed
large inclusion structures (Fig. 7J–L). In cells expressing
WT::RFP, nearly all of the protein was concentrated in an
inclusion, making it difﬁcult to visualize the boundaries of
the cell. Co-expression of WT::YFP and WT::RFP induced
the formation of inclusion structures that contained both pro-
teins, with the two ﬂuorophores completely overlapping in
localization (Fig. 8A–D). Similarly, co-expression of G37R
proteins fused to YFP (G37R::YFP) and RFP (G37R::RFP)
ﬂuorescent tags leads to the formation of inclusions in which
Figure 3. Paralysis develops earlier in G37R or L126Z mice that co-express WT hSOD1. (A and B) Plots of age to paralysis of mice from G37R (A) and L126Z
(B) crosses to Gurney and L76 mice. Endpoints were deﬁned as the point at which hind limb paralysis impedes access to food and water. Log-rank tests demon-
strated statistical differences in lifespan between homozygous G37R mice and G37R/SJLWT (P ≤ 0.0001), between G37R/CgWT (P ≤ 0.0005) and G37R/
L76WT (P ≤ 0.05) and between L126Z mice and L126Z/SJLWT (P ≤ 0.005), but not with L126Z/L76WT (P ¼ 0.8987). The number of mice of each genotype
is provided in Results.
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co-localization of SOD1::YFP with SOD1::RFP (WT or
G37R SOD1) appeared to be mediated by the SOD1 portion
of the protein because co-expression of YFP alone with
WT::RFP did not produce inclusions containing both ﬂuoro-
phores (Fig. 8I–L). Co-expression of G37R::YFP with
WT::RFP produced structures in which the G37R::YFP
protein appeared to be depositing on the surface of an
inclusion formed by the rapidly aggregating WT::RFP
protein (Fig. 8M–P). Reversal of the ﬂuorophores in which
WT::YFP was co-expressed with G37R::RFP produced the
same pattern, but in this case the central inclusion was
formed by the G37R::RFP, with WT::YFP depositing on the
surface (Fig. 8Q–T).
These patterns of interaction between WT and mutant
SOD1 fusion proteins were also seen when A4V::YFP
was co-expressed with WT::RFP (Fig. 9). We observed
some instances in which an inclusion formed by the
WT::RFP fusion was surrounded by the A4V::YFP fusion
protein (Fig. 9A–D). More rarely, we observed cells in
which it appeared that inclusions formed by A4V::YFP
fusion protein were adjacent to inclusions formed by
WT::RFP fusion protein (not shown). In the converse exper-
iment, at 48 h post-transfection, all cells that exhibited
inclusions formed by A4V::RFP fusion proteins were sur-
rounded by WT::YFP fusion proteins that appeared to be
deposited on the surface of the A4V::RFP inclusions
(Fig. 9E–H). In contrast, co-transfections of two mutant
SOD1::YFP fusion proteins that were differentially tagged
(A4V::YFP with G37R::RFP) produced inclusions in
which the two fusion proteins appeared to be homogenously
co-localized (Fig. 9I–L). Collectively, these data suggest
that WT and mutant SOD1 adopt conformations that do
not favor co-assembly into higher order structures. In con-
trast, the conformations adopted by A4V and G37R SOD1
are similar enough to facilitate a more intimate co-mingling
of the two proteins within the inclusion structure.
DISCUSSION
In the present study, we demonstrate that co-expression of
WT hSOD1 with fALS mutant hSOD1 accelerates the
course of disease in matings of three different strains of
mice expressing WT hSOD1 with two different lines of
mutant mice. The effect of WT hSOD1 mice on disease
in mice expressing mutant hSOD1 was inﬂuenced by the
nature of the mutation and the level of the mutant and
WT hSOD1 proteins expressed. Symptomatic mice
co-expressing WT and mutant SOD1 accumulate
detergent-insoluble aggregates of both proteins regardless
of whether the age to paralysis is altered. In cell models,
co-expression of WT hSOD1 with G37R or L126Z
hSOD1 diminished the capacity of the mutant protein to
form detergent-insoluble aggregates. Using variants of both
WT and mutant hSOD1 fused to ﬂuorescent tags, we visu-
alized inclusions generated in cells co-expressing WT and
mutant SOD1, ﬁnding evidence that WT and mutant
SOD1 do not readily interact to form homogenous aggre-
gates. From these observations, we cannot easily conclude
that the earlier development of paralysis observed in mice
Figure 4. Symptomatic mice accumulate signiﬁcant amounts of detergent-insoluble SOD1 aggregates at endstage. (A and C) Immunoblots of detergent-insoluble
(P2) and detergent-soluble (S1) fractions of spinal cord from transgenic mice. SOD1 protein was detected with an antibody that recognizes mouse and hSOD1
(A), or an antibody speciﬁc for hSOD1 (C). Note that the truncation mutant migrates more rapidly (black arrowhead) than WT hSOD1 (open arrowheads). (B and
D) Quantiﬁcation of aggregation index of total SOD1 in G37R/WT crosses (B), and quantiﬁcation of WT and L126Z protein levels in P2 fraction of L126Z/WT
mice (D). ∗P ≤ 0.05,
#P ≤ 0.005. Bars represent mean + SEM.
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more rapid formation of aggregated SOD1 proteins.
Acceleration of disease by co-expression of WT hSOD1
In matings of G37R and WT mice, we observed surprisingly
that double-transgenic progeny of G37R mice crossed with
the Gurney and L76WT strains of mice developed disease
earlier than mice homozygous for the G37R transgene,
with the age to paralysis appearing to be related to the
levels of WT hSOD1 expression. Within the data on the
crosses of these strains of mice, we can observe that the
background strain of the animals moderates the effect of
the WT hSOD1 on age to paralysis. G37R/SJLWT mice
show a slightly earlier development of paralysis than
G37R/CgWT mice. G37R/L76WT mice (congenic on the
C57BL6/J strain) show an age to paralysis that is somewhat
slower than that shown by G37R/CgWT mice. In this latter
case, we assume that the slower course of G37R/L76WT
mice is due to slightly lower expression of the WT hSOD1
transgene (Fig. 1). Importantly, all of the double-transgenic
animals in these studies were compared with littermates
born of the same breeders and thus the littermates harboring
only the G37R transgene would have similar mixtures of the
background strains as their double-transgenic littermates.
Thus, the dramatically accelerated course of disease in
G37R/WT mice of all three strains must be due to an
ability of the WT protein to either acquire a toxic property
or augment the toxicity of the G37R variant.
Given the magnitude of the effect of WT hSOD1
co-expression on the age to paralysis of G37R mice, it
appears that WT proteins possess the capacity to: (i) double
the toxicity of a given unit of G37R hSOD1, (ii) double the
steady-state level of the G37R protein by some means of
stabilization or (iii) acquire a level of toxicity essentially
equivalent to mutant SOD1. We know from previous work
that WT and G37R hSOD1 are able to form a dimeric
enzyme, and that at equilibrium we could expect that at
least 50% of the G37R protein would be heterodimerized
with WT protein (21). One possibility is that such heterodi-
mers protect the mutant protein from degradation and simply
increase the total dose of mutant SOD1 (13). However, in pre-
vious studies, we have demonstrated that the co-expression of
mutant SOD1 with a rapid rate of turnover with WT protein
does not result in a more rapid turnover of WT protein or a
slower turnover of the mutant protein (21). For the G37R
mutant, it seems unlikely that the WT protein would be able
to stabilize mutant SOD1 protein to a sufﬁcient degree to
increase the levels of the mutant protein by more than 2-fold
as would be required to explain why co-expression of the
WT protein in G37R mice causes paralysis earlier than
observed in the homozygous G37R mice. However, because
of the difﬁculty in distinguishing the G37R mutant from WT
protein in spinal cord extracts, we cannot be certain that
some type of stabilization has not occurred. In the crosses of
L126Z mice with WT SOD1 mice, the detection of both pro-
teins is much easier. In spinal cords of double-transgenic mice,
the aggregation of the mutant and WT proteins confounds
determination of whether the presence of the WT protein
changes the steady-state level of the mutant protein.
However, in the forebrain of symptomatic L126Z mice,
detergent-insoluble forms of the mutant protein are not
detected (see Supplementary Material, Fig. S3 of reference
22). Immunoblots of total protein in the forebrain do not
produce evidence that the steady-state levels of L126Z
protein increase when WT protein is co-expressed (Sup-
plementary Material, Fig. S6). Thus, although we cannot
completely rule out the possibility that the presence of WT
Figure 5. WT hSOD1 is present in detergent-insoluble fractions of spinal cords of G37R/SJLWT mice. (A–D) FTMS analyses of P2 (A and B) and S1 (C and D)
fractions from two different sets of spinal cord samples. For each sample, three spinal cords were combined (from different symptomatic G37R/SJLWT mice)
and extracted in detergent as described in Materials and Methods. Mass peaks indicative of WT and mutant SOD1 were found in both the S1 and P2 fractions.
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steady-state levels in spinal cord, we think that the weight of
evidence favors another explanation. Thus, we propose
that WT SOD1 acquires toxic properties through some type
of interaction with mutant SOD1. Recent demonstrations
that various forms of WT SOD1 possess toxicity lend credi-
bility to such a hypothesis (23,24).
In our study involving mice expressing L126Z/WT hSOD1,
we observed that the L126Z/SJLWT showed earlier paralysis
than mice expressing L126Z alone, as Deng et al.( 8) reported
in a similar cross, whereas L126Z/L76WT mice develop
disease at the same time as L126Z mice, similar to what
Bruijn et al.( 15) reported in crosses of L76WT mice to
G85R hSOD1 mice. In this cross, we are comparing SJLWT
mice with L76WT mice, which adds a complication in
regard to potential inﬂuences of background strain. Unfortu-
nately, the breeding of the CgWT Gurney strain to L126Z
mice failed to produce an adequate cohort of double-
transgenic animals. However, as noted above, the comparisons
in age to paralysis between L126Z/SJLWT mice included lit-
termates that were transgenic only for the L126Z transgene
and which would possess the same mixture of background
strains. Hence, we are conﬁdent that the earlier development
of paralysis in L126Z/SJLWT mice is due to an effect of the
co-expressed WT hSOD1. Because expression of L126Z
hSOD1 is above the threshold to induce disease, we are
looking only for an augmentation of toxicity. Similarly,
G85R mice used in the study by Bruijn et al.( 15) develop
disease spontaneously and thus assessed augmentation of tox-
icity by WT hSOD1. We conclude that the simplest expla-
nation for the accelerated disease in mice generated from
matings of Gurney WT and L126Z mice is that higher levels
of WT SOD1 expression in Gurney WT mice simply increase
the strength and frequency of interactions between WT and
mutant proteins and thus increase the opportunities to
produce toxic structures. We propose that this explanation
could also hold to explain how crosses of Gurney WT mice
with a line of G85R mice resulted in double-transgenic
progeny that developed paralysis earlier than mice expressing
the G85R mutant alone (11), whereas crosses of G85R mice
with L76WT mice produced no effect (15). We note that the
age to paralysis of G85R mice described by Wang et al.
(11) and that of G85R mice described by Bruijn et al.( 15)
were approximately the same,  12 months. Thus, we con-
clude that the discrepancy between the report by Wang et al.
(11) and Bruijn et al.( 15) is due to the differing levels of
expression by the lines of WT SOD1 mice used in the respect-
ive studies.
Figure 6. WT hSOD1 slows the aggregation of both G37R and L126Z hSOD1 in cultured cells. (A and C) Aggregate formation determined by immunoblot of
transiently transfected cells for 24 (A, upper panels) or 48 h (A, lower panels; and C). In co-transfections of WT and mutant hSOD1 or mutant hSOD1 and GFP
(the latter as a control for co-transfection), we used equimolar amounts of each plasmid, with the total amount of transfected protein remaining the same for all
reactions (4 mg). (B and D) Relative aggregation index of SOD1 proteins was calculated as P2/S1 ratios, and unpaired Student’s t-test were performed as stat-
istical analyses. Symbols over the bars indicate differences with WT hSOD1-transfected cells, or as indicated in the ﬁgure: ∗P ≤ 0.05,
#P ≤ 0.0005. Bars rep-
resent mean+SEM of a minimum of three independent transfection experiments.
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WT and mutant hSOD1, it is clear that the magnitude of the
effect of WT protein on the toxicity of mutant SOD1 is
related to the level of mutant SOD1 expression. There are
three examples of crosses between WT mice and mutant
mice in which the level of the mutant protein is below the
threshold to develop disease. These include a line of mice
that express the A4V mutant (8), mice that express G93A
mutant via a Thy1 promoter (10) and mice that express an
experimentally truncated SOD1 ending at residue 116
(T116X) (9). In each of these cases, mice heterozygous for
the mutant transgene do not develop disease, but mice
doubly transgenic for these mutant SOD1 transgenes and the
WT SOD1 (derived from the Gurney WT line) develop paraly-
sis by 12–18 months (8–10). Mice that express L126Z SOD1
at levels to induce paralysis by 12 months of age develop
paralysis by 7 months of age when doubly transgenic with
the Gurney WT SOD1 mice (8). Our L126Z mice express
mutant protein at a level that induces paralysis by 7 months
of age with the co-expression of WT SOD1 (via mating to
the Gurney WT) reducing the age to paralysis by 1–
2 months. In contrast, the effect of mating Gurney WT
SOD1 mice to Gurney G93A mice, which develop paralysis
at 130 days, was a change in age to paralysis of only
10 days earlier in mice transgenic for both mutant and WT
SOD1 (8). Thus, the magnitude of the effect WT SOD1 has
on the toxicity of mutant SOD1 is inversely proportional to
the level of mutant SOD1 that is expressed.
Another important point is that among the examples of large
effects of WT SOD1 on age to paralysis, T116X and L126Z
mutants would not be expected to be able to form normal
heterodimers with WT SOD1 due to loss of portions of the
Figure 7. Morphology of WT hSOD1 tagged with YFP (WT::YFP) and RFP (WT::RFP). WT::YFP produces a diffusely localized protein, whereas WT::RFP
produces inclusions. (A–I) HEK293FT transfected for 24 h with YFP alone (A–C), WT::YFP (D–F) or WT::RFP (G–I) were ﬁxed and visualized as described
in Materials and Methods. All images were captured using a 40x objective using epiﬂuorescence on an Olympus BX60 microscope with a color camera; bar 20
(A–C and G–I) or 50 (D–F) mm.
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less able to form normal dimeric enzyme (25,26). If normal
dimeric interactions between WT and mutant SOD1 were by
some manner responsible for stabilizing the mutant protein to
increase steady-state levels, then one might expect that these
poorly dimerizing mutants would be less affected by co-
expression of WT SOD1. Clearly, however, the toxicity of these
mutants is dramatically augmented by the presence of WT
protein. These observations also suggest that mutant proteins are
probably interacting with WT SOD1 via some mechanism other
thanthenormaldimerinterfacetoproducetheaugmentedtoxicity.
Earlier disease in mutant/WT mice is associated
with aggregated SOD1
In all our double-transgenic mutant/WT hSOD1 mice, hind
limb weakness and paralysis were accompanied by the
accumulation, in the spinal cord, of detergent-insoluble
species of WT hSOD1. Thus, the earlier appearance of paraly-
tic disease led to a coincident earlier appearance of detergent-
insoluble SOD1 aggregates. In tissues from L126Z/WT
double-transgenic mice, it is possible to detect the WT
protein in detergent-insoluble fractions by immunoblot due
to the smaller size of the truncation mutant, relative to WT
hSOD1. In the tissues from G37R/WT double-transgenic
mice, we utilized mass spectroscopy approaches to identify
WT and mutant proteins in insoluble fractions. Thus, in both
cases, WT SOD1 acquired insolubility in symptomatic mice.
In spinal cords of symptomatic L126Z/WT mice, we easily
detected detergent-insoluble forms of WT SOD1 by immuno-
blotting. Importantly, we demonstrate that symptomatic mice
derived from mating L126Z SOD1 mice with L76WT SOD1
mice accumulate detergent-insoluble forms of WT hSOD1
despite the fact that there was no change in the age to
Figure 8. Visualization of interactions between WT and G37R hSOD1. (A–T) HEK293FT were co-transfected with the indicated SOD1::YFP and SOD1::RFP
constructs. Although expression of the same SOD1 protein with different tags (YFP and RFP tags) produced inclusions in which both ﬂuorophores co-localize
(WT::YFP + WT::RFP in A–D, G37R::YFP + G37R::RFP in E–H), YFP did not co-localize in inclusions containing WT::RFP (I–L). Co-expression of
WT- and G37R-tagged proteins (G37R::YFP + WT::RFP in M–P, and WT::YFP + G37R::RFP in Q–T) produced inclusion structures consisting of a core
of the RFP-tagged protein surrounded by the YFP-tagged protein. All images were captured with a 60x water immersion objective and a spinning disk confocal
microscope; bars 10 mm.
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protein was purely incidental to the disease. This ﬁnding dis-
connects the co-aggregation of WT and mutant SOD1 to the
processes responsible for decreasing the age to paralysis
since L126Z/L76WT mice develop paralysis at an age
similar to heterozygous mice expressing only the L126Z
variant.
Ourﬁndingsincellmodelsofaggregationareconsistentwith
the idea that the capture of WT hSOD1 in insoluble aggregates
could be secondary to the assembly of mutant SOD1 into inso-
luble structures. Studies involving ﬂuorescently tagged ver-
sions of WT and G37R SOD1 produce images that delineate
interactions between WT and mutant proteins in aggregate
assembly. WT::YFP fusion proteins do not readily form
inclusions, whereas G37R::RFP fusion proteins readily gener-
ate inclusions. When inclusions are rapidly formed by
G37R::RFP or A4V::RFP, the co-expressed WT::YFP deposits
around the outer edge of the core of the inclusion. In contrast,
inclusions formed in cells co-expressing WT::YFP and
WT::RFP, or G37R::YFP and G37R::RFP, appear to contain
interlaced assemblies of both proteins. The co-expression of
A4V::YFP with G37R::RFP also produced perfectly interlaced
inclusions. Thus, the exclusion of WT::YFP to the periphery of
inclusions formed by mutant SOD1::RFP fusion proteins indi-
cates that WT and mutant SOD1 do not interact effectively as
aggregates assemble.
In a recent study of mice that co-express WT SOD1 with
G85R hSOD1, immunoblots of detergent-insoluble protein in
the spinal cord demonstrated immunoreactive bands that
showed electrophoretic migrations that were suggestive of
aberrant disulﬁde cross-links between WT and G85R mutant
SOD1 (11). The banding pattern was also interpreted to indi-
cate abnormal disulﬁde-linked homodimers of G85R and
homodimers of WT hSOD1 were present. The relative
amount of WT and G85R that were cross-linked in aberrant
dimers was not quantiﬁed but it appeared to be a relatively
minor percentage. Still, this ﬁnding would suggest that some
mutant and WT proteins are in close proximity within aggre-
gates formed in spinal cords of these mice. In our cell model,
we show images in which WT SOD1 appears to be deposited
on the surface of mutant SOD1 inclusions and vice versa. We
suggest that if the structures we observe in the cell model
occur between WT and mutant SOD1 in vivo, then there
would be ample opportunity for WT and mutant SOD1 to
be in close enough contact to permit aberrant disulﬁde cross-
links. It is also possible that the much slower kinetics of
aggregation that occur in vivo provide greater opportunity
for WT protein to be incorporated into growing aggregates
of the mutant protein. We suggest that our ﬁndings in the
cell model indicate that such interactions are probably not
favored but we cannot exclude the possibility that they occur.
Mechanisms of toxicity
The foregoing discussion paints a view in which the aggrega-
tion of mutant SOD1 is proposed to be secondary to toxicity.
However, we do not believe that this view is entirely correct.
The outcomes of our study of the G37R mice are potentially
very informative regarding aggregation and toxicity. Mice
homozygous for the G37R transgene develop disease,
whereas mice with 50% less expression, due to heterozygosity
for the transgene, do not (20). Increasing total SOD1
Figure 9. WT and A4V SOD1 fusion proteins do not form homogenous inclusions in which both ﬂuorophores co-localize. HEK293FT cells were co-transfected
with the indicated SOD1 constructs for 24 (A–D)o r4 8( E–L) h. Co-expression of A4V::YFP and G37R::RFP produces homogenous inclusions containing both
proteins (I–L). Images were captured with a 60x water immersion objective in a spinning disc confocal microscope; bars 10 mm.
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levels equivalent to or slightly above the G37R mutant
protein also produces disease. In this later case, mice reach
endstage paralysis sooner than mice homozygous for G37R.
Importantly, the level of expression of mutant SOD1 or
mutant/WT SOD1 that is required to induce disease is identi-
cal to the level required to induce the formation of large
detergent-insoluble aggregates. Because we know from a
variety of studies of protein aggregation that oligomeric
assemblies are precursors to larger aggregates (for review,
see 27,28), we assume that the large detergent-insoluble
aggregates detected in symptomatic mice are derived from
some type of oligomeric precursor. Our ﬁndings in the
G37R mice suggest that the threshold of mutant or mutant/
WT SOD1 that is required to induce toxicity is linked to the
threshold required to induce aggregation and presumably oli-
gomerization. The simplest scenario is that a population of oli-
gomeric structures is generated early in the course of disease,
with some of these structures possessing toxicity (Fig. 10).
At present, we lack evidence for the existence of toxic oli-
gomeric structures and thus the model we present is speculat-
ive. It is possible that WT SOD1 has some indirect effect on
the biology of the system to change the way that mutant
SOD1 is processed, leading to a heightened generation of
forms of the mutant protein that are toxic. However, our cell
culture studies indicate that WT protein can modulate the
aggregation of mutant SOD1 and it is thus tempting to
suggest that one mechanism by which WT SOD1 accelerates
the course of disease is by oligomerizing with mutant SOD1
to produce toxic species that in some manner mediate early
events in disease course. We are reasonably sure that early
in the course of disease, when the ﬁrst pathologic features
ﬁrst appear, the vast majority of the mutant protein is
soluble and yet to have assembled into large aggregates (6)
and that the formation of the large aggregates, which occurs
in the interval between ﬁrst visible symptoms and paralysis
(4–6), may potentially mediate events involved in disease pro-
gression (Supplementary Material, Fig. S7) (3,7). Thus, we
have proposed that more than one molecular form of mutant
SOD1 mediates toxic events in disease pathogenesis, with
large detergent-insoluble aggregates playing roles late in
disease and detergent-soluble forms of the protein involved
in events that initiate disease (3,6). If, as indicated in these
prior studies, soluble forms of mutant SOD1 are involved in
events that initiate disease, then it appears that co-expression
of WT SOD1 enhances the generation of these toxic soluble
species.
What do these studies tell us about the human disease? The
collection of studies involving transgenic mice that co-express
mutant and WT hSOD1 indicate that WT protein has the
potential to either inﬂuence the toxicity of the mutant
protein or to acquire toxic properties. In either case, the age
to paralysis is noticeably decreased in mice when WT
hSOD1 is co-expressed with mutant hSOD1. However, in
the mouse models, it is clear that the mutant protein need
not partner with WT hSOD1 for disease to occur because all
examples of transgenic mice that model SOD1-linked ALS
were initially made by expressing the mutant human gene
alone. In humans, the extent to which WT SOD1 inﬂuences
the onset or progression of disease is unclear. The vast
Figure 10. A model for the maturation and aggregation of WT and fALS mutant SOD1. The steps in the normal maturation of mutant and WT SOD1 are not
completely understood. It is likely that the binding of zinc (Zn) is one of the ﬁrst steps in maturation. With the binding of Zn, the protein may be able to form a
weakly interacting dimer. Oxidation of the normal C57 to C146 disulﬁde bond may or may not occur prior to the binding of copper (Cu); however once Cu is
bound and the disulﬁde is formed, a very stable dimeric enzyme is created. Some of the fALS mutants appear to be able to properly mature, whereas others, such
as the L126Z truncation mutant, cannot. We suggest that toxic oligomeric forms of mutant SOD1 may be generated early in the course of disease, with WT
protein possibly being able to co-oligomerize with the mutant protein to generate toxic species responsible, decreasing the age to paralysis by initiating
disease earlier. Late in disease, WT SOD1 may be captured in larger aggregates of mutant SOD1. WT SOD1, when over-expressed in transgenic mice, can
produce large detergent-insoluble aggregates. Whether WT SOD1 can also produce toxic oligomeric assemblies is unknown.
Human Molecular Genetics, 2010, Vol. 19, No. 24 4785majority of patients with SOD1-linked fALS are heterozygous
for the disease-causing mutation. One notable exception is
disease caused by the mutation of Asp 90 to Ala (D90A)
(29). In most families, this mutation only causes disease when
individuals are homozygous for the mutation. However, there
are a few rare families in which the D90A mutation acts as a
dominant mutation to cause disease in a heterozygous state
(30). Thus, if the WT protein plays some role in modulating
the toxicity of D90A SOD1, we have examples in which the
WT protein would seem to be negating toxicity in pedigrees
in which disease is present only when homozygous for the
mutation and examples in which WT protein could promote
the toxicity of the mutant protein in pedigrees in which
disease is present in patients heterozygous for the D90A
mutation. There are a few rare examples of patients who are
homozygous for a mutation that is otherwise dominantly inher-
ited. In one case (N86S mutation), the homozygous patient
developed a rapidly progressing disease at a very young age
(31). However, in another case (L126S mutation), the homozy-
gouspatientdevelopeddiseaseatanagetypicalforALS,butthe
rateofprogressionwasextremelyrapid(32).Collectively,these
studies indicate that, similar to the mouse studies, the presence
of WT hSOD1 is not obligatory for the mutant protein to exert
toxicity. The unresolved questions are whether WT protein
may be involved in the generation of toxic forms of the
mutant protein in humans and whether the involvement WT
protein varies with different mutations.
Conclusions
Our ﬁndings indicate that the effect of WT SOD1 on the tox-
icity of mutant SOD1 is inﬂuenced by both the nature of the
fALS mutation with which it is co-expressed and the level
of WT SOD1 expression. Although WT SOD1 is present in
insoluble aggregates found in symptomatic double-transgenic
mice, we provide the ﬁrst evidence that dissociates WT
SOD1 co-aggregation from the earlier development of paraly-
sis. From cell culture models of aggregation, we ﬁnd that WT
SOD1 modulates the aggregation of the mutant protein to slow
the formation of large detergent-insoluble structures. Our
study of SOD1::YFP fusion proteins indicates that WT and
mutant SOD1 do not intimately co-assemble in cellular aggre-
gates. Together, these ﬁndings implicate soluble assemblies of
WT and mutant SOD1 as possible mediators of toxic processes
involved in initiating motor neuron disease. The extent to
which such assemblies are involved in human disease, where
expression levels of both mutant and WT SOD1 protein are
much lower than the mouse models, is likely to be dependent
on the nature of the fALS mutation.
MATERIALS AND METHODS
Transgenic mice
All the strains of transgenic mice used in this study have been
previously described. The PrP.SOD1-G37R SOD1 line 110
mice were generated by a vector that utilized the mouse
prion protein promoter (MoPrP.Xho) containing a hSOD1
cDNA with the G37R mutation (20). These mice were main-
tained in a hybrid background of C57BL/6J and C3H/HeJ.
All other strains of mice used in this study were generated
with genomic fragments of the hSOD1 gene. The L126Z
SOD1 line 45 used a modiﬁed genomic fragment in which
exons 3–5 of the human gene were fused (19) and a stop
codon was inserted at codon 127. These mice were maintained
in a hybrid background of C57BL/6J and C3H/HeJ. Mice
expressing WT hSOD1 that we used included a line developed
by Gurney et al.( 17), maintained in both hybrid backgrounds
of C57BL/6J × SJL and in a congenic background of C57BL/
6J (these strains are designated SJLWT and CgWT, respect-
ively), and WT line 76 mice (designated L76WT) (16) main-
tained in a congenic background of C57BL/6J mice. The
congenic Tg(SOD1)Gur2/J mice were graciously provided
by Dr Gregory Cox (Jackson Laboratories, Bar Harbor, ME,
USA). All studies involving mice were approved by the Insti-
tutional Animal Care and Use Committee at the University of
Florida.
For the identiﬁcation of genotype, DNA from mouse tail
biopsy was extracted by digesting tissue (0.6 cm length) in
600 ml of TNES buffer (50 mM Tris base, pH 7.5; 400 mM
NaCl; 100 mM EDTA, pH 8.0; 0.5% SDS) with 18 ml of Pro-
teinase K at 20 mg/ml. After being kept overnight in a 558C
water bath, 167 ml of supersaturated 6 M NaCl was added to
each sample, mixed and then centrifuged at 16 100g for
5 min. A total of 650 ml of supernatant was removed and
placed into a new microfuge tube, then centrifuged again
before 600 ml of supernatant was moved to a new tube and
mixed with an equal volume of cold 100% ethanol. DNA
was then pelleted by centrifuging at 14 000 r.p.m. for 5 min
and washed with 1 ml of cold 70% ethanol before centrifuging
again for 2 min. The ﬁnal DNA pellet was resuspended in
200 ml of TE buffer (10 mM Tris base, pH 7.5; 1 mM EDTA,
pH 8.0).
The DNA extracted from mouse tail was analyzed by PCR
using the following primers. For the L126Z and WT hSOD1
lines of mice, we used two primers: Hu-S primer (5′-TCA
AGC GAT TCT CCT GCC T); H/M-AS primer (5′-CAC
ATT GCC CAR GTC TCC A; R ¼ A/G). For the G37R line
110 hSOD1 mice, we used three primers: PrP-S primer
(5′-GGG ACT ATG TGG ACT GAT GTC GG); PrP-AS
primer (5′-CCA AGC CTA GAC CAC GAG AAT GC);
HuSOD1-S (5′-GTC GAC AAG CAT GGC CAC GAA
GGC CGT GTG C). PCR reactions were performed using
Taq DNA polymerase and PCR reagents from New England
Biolabs (Ipswich, MA, USA) following the manufacturer’s
protocol. The settings for the thermocycler were as follows:
948C for 5 min; 35 cycles of 948C for 30 s; 608C for 1 min;
728C for 5 min; 728C for 10 min. The PCR products were
the following: the L126Z hSOD1 transgene produced a
fragment of  500 bp, the WT hSOD1 transgene produced a
fragment of  1200 bp and G37R hSOD1 transgene produced
a fragment of  500 bp. Endogenous mouse prn-p genes
produce fragments of  750 bp and served as a positive
control.
SOD1 cDNA expression plasmids
All of the non-tagged WT SOD1 and ALS-associated mutant
hSOD1 cDNAs were expressed from plasmids based on the
mammalian pEF-BOS expression vector, and have been
4786 Human Molecular Genetics, 2010, Vol. 19, No. 24previously described (19,33). GFP was expressed in
pcDNA3.1 as described previously (12).
SOD1 fusion protein cDNA variants were created from an
expression vector (pPD30.38) that contains WT hSOD1
fused to eYFP (yellow ﬂuorescent protein), which was
kindly provided by Dr Rick Morimoto (Northwestern Univer-
sity). This SOD1::eYFP construct contains a 27 bp linker
(translated sequence—LQLKLQASA) between SOD1 and
YFP that was modiﬁed to include an SalI restriction site (trans-
lated sequence—LQSTLQASA). This SOD1::YFP DNA
fusion construct was then cloned into our mammalian
pEF-BOS expression vector. From this initial SOD1::YFP
expression plasmid, we generated vectors for A4V::YFP and
G37R::YFP. Additionally, we also created a control plasmid
in pEF-BOS for eYFP (termed YFP). Similar to SOD1::YFP
fusion proteins, we created SOD1 fusion proteins with a red
ﬂuorescent protein tag [RFP, Turbo RFP cDNA obtained
from the pTRIPZ empty vector available at Open Biosystems
(Huntsville, AL, USA)] by replacing the YFP tag with the RFP
tag. In this way, we created WT::RFP, A4V::RFP and
G37R::RFP constructs along with a vector to express RFP
alone. All cell culture studies of SOD1 aggregation used
HEK293FT cells (Invitrogen, Carlsbad, CA, USA).
Northern blotting
Fresh spinal cords were harvested from 4-month-old mice,
with one-half of the cord immediately used for RNA extrac-
tion and the other half frozen for analyses of protein levels.
Extraction of spinal cord mRNA was performed using
TRIzol (Invitrogen) as described by the manufacturer. Five
micrograms of total RNA was electrophoresed in formal-
dehyde–agarose gels and then transferred onto a nylon mem-
brane by capillary action using 10x SSC buffer (1.5 M NaCl,
150 mM sodium citrate, in distilled water treated with diethyl
pyrocarbonate). The nylon membrane was then cross-linked,
and pre-hybridized for 1 h at 658C with hybridization buffer
(1% BSA, 1 mM EDTA at pH 8.0, 0.5 M NaHPO4 at pH 7.2,
7% SDS) followed by hybridization at 658C with the
32P-labeled cDNA probes (at  1.4 × 10
6 c.p.m./ml) for
12 h. As probes, we generated a fragment of hSOD1 cDNA
and a fragment that recognizes endogenous mouse PrP
mRNA, the latter serving as a loading control. Probes were
labeled using the DNA-Ready to Go-label beads
32P-dCTP
from GE Healthcare (Pittsburgh, PA, USA) and puriﬁed
with Illustra ProbeQuant G-50 Micro Columns from GE
Healthcare as described by the manufacturer. After hybridiz-
ation, membranes were washed three times for 30 min with
wash buffer 1 (0.1% BSA, 1 mM EDTA at pH 8.0, 40 mM
NaHPO4 at pH 7.2, 5% SDS) at 658C. Two more washes
were then performed with wash buffer 2 (1 mM EDTA at pH
8.0, 40 mM NaHPO4 at pH 7.2, 1% SDS). Membranes were
then exposed to ﬁlm and developed after 24 h or imaged by
phosphorimaging on a Molecular Dynamics Instrument
(Bio-Rad Laboratories, Hercules, CA, USA) . Northern blot
analyses were performed on a total of three spinal cords
from each of WT mouse strains. Band intensities from the
northern blots quantiﬁed by phosphorimaging were calculated
using Quantity One 4.6.5 software (Bio-Rad Laboratories). In
the quantiﬁcation of SOD1 mRNA levels, we normalized the
values of endogenous prion protein mRNA, which served as
a loading control. The statistical signiﬁcance of differences
in mRNA levels was determined by unpaired Student’s t-tests.
Determination of total SOD1 protein levels
in the spinal cord
Spinal cords were dissolved by sonication in ﬁve volumes (by
weight) of 1x TEN buffer (10 mM Tris, pH 7.5; 1 mM EDTA,
pH 8.0; 100 mM NaCl) with protease inhibitor cocktail at
1:100. A brief 800g centrifugation for 10 min was performed
to discard cell debris. Protein concentrations in the supernatant
fraction,whichrepresentstotalextractedprotein,weremeasured
byBCAassay(PierceBiotechnology,Rockford,IL, USA).Five
microgram of protein was electrophoresed in 18% SDS–PAGE
gels, transferredtomembranesandimmunoblottedwith ananti-
body(1:2500,overnight)thatrecognizesmouseandhSOD1(34)
or an antibody (1:2500 overnight) that recognizes only hSOD1
(33) as indicated in the ﬁgure legends. Blots were also probed
(1:5000, overnight) with an antibody that recognizes
b-tubulin-III for loading control. A secondary goat anti-rabbit
IgG (1:5000, 1 h) was used to detect primary antibodies. Band
intensitiesfromtheimmunoblotswerecalculatedusingtheFuji-
ﬁlm imaging system (FUJIFILM Life Science, Valhalla, NY,
USA). In the quantiﬁcation of SOD1 protein levels, we normal-
ized the values to the tubulin-loading control.
Detergent extraction of SOD1 aggregates
This assay generates two protein fractions termed S1
(detergent-soluble) and P2 (detergent-insoluble), the latter
containing aggregated forms of mutant SOD1, as described
previously (3,35). Detergent extraction of cultured cells was
performed as described in the foregoing reports; however,
for spinal cord samples, slight modiﬁcations of the protocol
were followed to obtain higher levels of extracted protein. A
total of 300 ml of spinal cord crude supernatant was extracted
by adding an equal volume of buffer to produce a ﬁnal concen-
tration of 10 mM Tris, pH 7.5; 1 mM EDTA, pH 8.0; 100 mM
NaCl; 0.5% NP-40, 1:100 v/v protease inhibitor cocktail.
The mixture was sonicated three times for 10 s each before
centrifugation at .100 000g for 5 min in a Beckman
AirFuge (Brea, CA, USA) to produce supernatant 1 (S1) and
pellet (P1) fractions. The P1 fractions were then washed
with the same extraction buffer (sonicated twice, 15 s each)
and centrifuged at .100 000g for 5 min. The supernatant
was discarded and the remaining pellet represented the
detergent-insoluble (P2) fraction, which was resuspended in
a buffer containing SDS and deoxycholate (10 mM Tris, pH
7.5; 1 mM EDTA, pH 8.0; 100 mM NaCl; 0.5% NP-40,
0.25% SDS, 0.5% deoxycholate, 1:100 v/v protease inhibitor
cocktail). The total volumes corresponding to S1 and P2 frac-
tions were of 600 and 100 ml, respectively. Protein concen-
trations of S1 and P2 fractions were determined by BCA
assay, as described by the manufacturer (Pierce Biotechnol-
ogy). For SDS–PAGE and immunoblot analyses, 5 mgo f
protein from S1 and 20 mg of protein from P2 were used. In
some of the SDS–PAGE analyses, reducing agents were
omitted from the loading and running buffers in order to
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following procedures described previously (6,36).
Analyses of S1 and P2 fractions by FTMS
FTMS analyses of S1 and P2 of spinal cords of two different
G37R/SJLWT samples were performed as described pre-
viously (12). Here, each spinal cord sample was extracted in
detergent to obtain S1 and P2 fractions from three combined
spinal cords (1.2 ml of S1 and 600 ml of P2). The entire P2
fraction was analyzed by HPLC followed by FTMS to identify
WT and mutant hSOD1 mass signatures.
Immunocytochemistry
Transfection of HEK293FT for immunocytochemistry was
performed on glass coverslips that were previously coated
with 0.5 mg/ml poly-L-lysine in 1x phosphate-buffered saline
(PBS) solution. Lipofectamine 2000 was used to transfect
2 mg of expression vector per well following the manufac-
turer’s protocol (Invitrogen). Transfected cells were then
ﬁxed with 4% paraformaldehyde in 1x PBS solution for
15 min. Additional staining was performed to visualize the
nuclei, using DAPI solution (4′,6-diamidino-2-phenylindole,
dihydrochloride, stock 14.3 mM from Invitrogen) at 1:2000
for a minimum of 10 min. Fluorescence was visualized by epi-
ﬂuorescence on an Olympus BX60 microscope with a color
camera and by confocal microscopy on an Olympus
IX81-DSU spinning disk confocal microscope indicated in
the ﬁgure legends.
Quantitation of immunoblots
Quantiﬁcation of the SOD1 protein in detergent-insoluble and
detergent-soluble fractions was performed by measuring the
band intensity of SOD1 in each lane using a Fuji Imaging
system (FUJIFILM Life Science, Stamford, CT USA). For
immunoblots of S1 fractions, we load 5 mg of total protein,
and for the P2 fractions, we load 20 mg of total protein.
Protein concentrations of S1 and P2 fractions were determined
by BCA assay, as described by the manufacturer (Pierce Bio-
technology). The untransfected cells served as a control.
Aggregation index was calculated as the ratio of the band
intensity in the detergent-insoluble fraction (P2) to that of
the detergent-soluble fraction (S1). Note that the amount of
protein loaded on the gel for P2 fractions is 4-fold more
than the S1 fraction. The mean and standard error of the
mean (SEM) were calculated for the aggregation index of
each sample in each experiment. In each cell culture exper-
iment, we included a positive control, which consisted of
transfection of expression vectors for A4V SOD1. To normal-
ize variation in data between experiments, relative values of
aggregation index are normalized to P2/S1 value of A4V at
24 h transfection (set to 1) (3).
Statistical analyses
All statistical analyses were performed using GraphPad
PRISM 5.01 Software (La Jolla, CA, USA). The speciﬁc
statistical method used in analyzing the data is noted in the
ﬁgure legends.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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